Takeda Presents New Phase 3 Data Showing Oveporexton Improves Daily Functioning, Cognition, and Sleep in Narcolepsy Type 1 Takeda has unveiled additional findings from its pivotal Phase 3 clinical development…
OM Pharma Presents Preliminary REACH Study Findings Demonstrating Real-World Benefits of Broncho-Vaxom® in Preventing Recurrent Respiratory Tract Infections OM Pharma has announced the presentation of preliminary results from its landmark…
Incyte Reports Positive Phase 3 frontMIND Results Showing Tafasitamab and Lenalidomide Plus R-CHOP Improves Outcomes in High-Risk DLBCL and HGBL Incyte has announced positive results from its pivotal Phase 3…
Biocytogen’s Boston Research Facility Earns AAALAC International Full Accreditation, Reinforcing Commitment to Scientific Excellence and Animal Welfare Biocytogen has announced a significant achievement for its U.S. research operations, revealing that…
Sumitomo Pharma America Highlights New Clinical and Translational Research for Nuvisertib and Enzomenib at EHA 2026 Sumitomo Pharma America, Inc. (SMPA) has unveiled new clinical and translational research findings at…
Cellares Secures Additional $50 Million Investment, Expanding Series D Financing to $327 Million to Accelerate Global Cell Therapy Manufacturing Network Cellares, the world’s first Integrated Development and Manufacturing Organization (IDMO)…
Arialys Therapeutics Advances ART5803 Development With Phase 2 Progress and FDA Clearance for New Clinical Study in Anti-NMDA Receptor Encephalitis Arialys Therapeutics, a clinical-stage biotechnology company focused on developing precision…
Atara Biotherapeutics Announces Board Transition, Welcomes Veteran Investor Brian Cherry as Director Atara Biotherapeutics, Inc., a clinical-stage biotechnology company focused on advancing T-cell immunotherapies for cancer and autoimmune diseases, has…
Otsuka Completes Acquisition of Transcend Therapeutics to Advance Development of Innovative PTSD Treatment Otsuka America, Inc., a subsidiary of the global healthcare company Otsuka Pharmaceutical Co., Ltd., has completed its…
Gilead Sciences Donates More Than 2,000 Vials of Remdesivir to Support Uganda’s Ebola Bundibugyo Outbreak Response Gilead Sciences has announced the donation of more than 2,000 vials of its intravenous…
BeOne Medicines Showcases Promising Hematology Pipeline Data at EHA 2026, Highlighting Advances in BTK Degradation and Time-Limited Therapies BeOne Medicines Ltd., a global oncology company focused on developing innovative treatments…
Cepheid Donates Hemorrhagic Fever Tests to Support Ebola Outbreak Response in Democratic Republic of the Congo and Uganda Cepheid, a molecular diagnostics company and part of Danaher Corporation, has announced…